---
schema_version: "secwatch.filing_event.v1"
accession: "0001808805-21-000016"
form_type: "8-K"
ticker: "NAUT"
cik: "0001808805"
company_name: "Nautilus Biotechnology, Inc."
filed_at: "2021-11-02T23:59:59+00:00"
generated_at: "2026-06-28T15:19:27.893971+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Nautilus Q3 net loss widens to $14.5M; OpEx up 262%; cash at $374M

## Summary
- Net loss of $14.5M for Q3 2021 vs. $4.0M loss in Q3 2020.
- Operating expenses $14.6M, up 262% YoY on higher headcount and public-company costs.
- Cash, cash equivalents and investments totaled $374.0M at September 30, 2021.
- Strategic partnership with Abcam and two new research collaborations (pharma and MD Anderson).
- Published theoretical foundation for PrISM single-molecule protein identification method.

## SEC filing metadata
- accession: 0001808805-21-000016
- form_type: 8-K
- ticker: NAUT
- cik: 0001808805
- company_name: Nautilus Biotechnology, Inc.
- filed_at: 2021-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808805/000180880521000016/0001808805-21-000016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808805/000180880521000016/naut-20211102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001808805-21-000016
- JSON: https://secwatch.observer/filing/0001808805-21-000016.json
- Plain text: https://secwatch.observer/filing/0001808805-21-000016.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.